CoChat
Sign Up
Cited by 2,086Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and MetabolismPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes

Yang, Qin, Graham, Timothy E., Mody, Nimesh, Preitner, Frederic, Peroni, Odile D., Zabolotny, Janice M., Kotani, Ko, Quadro, Loredana, Kahn, Barbara B.·2005·Nature
DOI 10.1038/nature03711
Open this paper in CoChat — free account

Abstract

In obesity and type 2 diabetes, expression of the GLUT4 glucose transporter is decreased selectively in adipocytes. Adipose-specific Glut4 (also known as Slc2a4) knockout (adipose-Glut4(-/-)) mice show insulin resistance secondarily in muscle and liver. Here we show, using DNA arrays, that expression of retinol binding protein-4 (RBP4) is elevated in adipose tissue of adipose-Glut4(-/-) mice. We show that serum RBP4 levels are elevated in insulin-resistant mice and humans with obesity and type 2 diabetes. RBP4 levels are normalized by rosiglitazone, an insulin-sensitizing drug. Transgenic overexpression of human RBP4 or injection of recombinant RBP4 in normal mice causes insulin resistance. Conversely, genetic deletion of Rbp4 enhances insulin sensitivity. Fenretinide, a synthetic retinoid that increases urinary excretion of RBP4, normalizes serum RBP4 levels and improves insulin resistance and glucose intolerance in mice with obesity induced by a high-fat diet. Increasing serum RBP4 induces hepatic expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK) and impairs insulin signalling in muscle. Thus, RBP4 is an adipocyte-derived 'signal' that may contribute to the pathogenesis of type 2 diabetes. Lowering RBP4 could be a new strategy for treating type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.1038/nature03711

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Kotani, K., Kim, Y. B., Peroni, O., Mundt, A. & Kahn, B. B. Rosiglitazone treatment normalizes glucose tolerance in adipose-specific GLUT4 knockout mice but renders muscle-specific GLUT4 knockout more diabetic [abstract]. Diabetes 50, A274 (2001)

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., & Kahn, B. B.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Columbia University (US)
Corresponding author
Kahn, Barbara B.
ORCID
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2005-07
Volume
436
Issue
7049
Pages
356-362
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
DOI
10.1038/nature03711
OpenAlex
W2092136583
Cited by
2,086
References
50
Citations by year
2026: 43 · 2025: 50 · 2024: 80 · 2023: 53 · 2022: 85 · 2021: 86 · 2020: 95 · 2019: 69 · 2018: 76 · 2017: 91 · 2016: 88 · 2015: 120 · 2014: 115 · 2013: 124 · 2012: 135
FWCI
89.83
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK043051)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
retinol-binding protein 4, insulin resistance, type 2 diabetes, obesity, GLUT4, adipose tissue, rosiglitazone, fenretinide, phosphoenolpyruvate carboxykinase, hepatic gluconeogenesis, impaired glucose tolerance
MeSH terms
Rosiglitazone, Adipose Tissue, Animals, Diabetes Mellitus, Type 2, Disease Models, Animal, Gene Expression Regulation, Insulin, Insulin Resistance, Liver, Monosaccharide Transport Proteins, Muscle Proteins, Muscles, Obesity, Phosphoenolpyruvate Carboxykinase (GTP), Retinol-Binding Proteins, Signal Transduction, Mice, Knockout, Oligonucleotide Array Sequence Analysis, Hepatocytes, Thiazolidinediones, Glucose Transporter Type 4, Mice, Retinol-Binding Proteins, Plasma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review